• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

临床孤立综合征患者脑脊液中的轴突损伤标志物有助于提高预测其转化为确诊多发性硬化症的准确性。

Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.

作者信息

Brettschneider J, Petzold A, Junker A, Tumani H

机构信息

Department of Neurology, University of Ulm, Germany.

出版信息

Mult Scler. 2006 Apr;12(2):143-8. doi: 10.1191/135248506ms1263oa.

DOI:10.1191/135248506ms1263oa
PMID:16629417
Abstract

Clinically isolated syndrome (CIS) represents the earliest phase of multiple sclerosis (MS). This study tested whether biomarkers for axonal degeneration can improve upon sensitivity and specificity of magnetic resonance imaging (MRI) parameters in predicting conversion from CIS to MS. Patients with CIS (n = 52), relapsing-remitting MS (RRMS, n = 38) and age-matched controls (n = 25) were included. Cerebrospinal fluid (CSF) levels of tau and neurofilaments (NfHSMI35) were measured using ELISA. The MRI T2-lesion load and the Expanded Disability Status Scale (EDSS) were recorded. CSF tau and NfHSMI35 were elevated in CIS compared to controls (P<0.05). RRMS patients with acute relapse had higher NfHSMI35 levels than stable patients. Tau and NfHSMI35 levels correlated with EDSS in CIS and RRMS. In RRMS, the number of T2-lesions correlated with tau levels (R = 0.53, P = 0.01). The sensitivity predicting the conversion from CIS to MS was higher for the combination of CSF markers (either tau or NfHSMI35 elevated) than for MRI (40 versus 34%), but could be further increased to 60% if CSF and MRI criteria were combined. Similarly, the combination of tau and NfHSMI35 showed higher specificity (94%) than MRI (82%). Tau and NfHSMI35 are valuable biomarkers for axonal damage in the CIS patients. Predicting conversion from CIS to MS can be improved if CSF markers are combined with MRI.

摘要

临床孤立综合征(CIS)是多发性硬化症(MS)的最早阶段。本研究测试了轴突退变生物标志物能否提高磁共振成像(MRI)参数预测CIS转化为MS的敏感性和特异性。纳入了CIS患者(n = 52)、复发缓解型MS(RRMS,n = 38)和年龄匹配的对照组(n = 25)。使用酶联免疫吸附测定法(ELISA)测量脑脊液(CSF)中tau蛋白和神经丝(NfHSMI35)的水平。记录MRI T2病灶负荷和扩展残疾状态量表(EDSS)。与对照组相比,CIS患者的CSF tau蛋白和NfHSMI35升高(P<0.05)。急性复发的RRMS患者的NfHSMI35水平高于病情稳定的患者。在CIS和RRMS中,tau蛋白和NfHSMI35水平与EDSS相关。在RRMS中,T2病灶数量与tau蛋白水平相关(R = 0.53,P = 0.01)。脑脊液标志物组合(tau蛋白或NfHSMI35升高)预测CIS转化为MS的敏感性高于MRI(40%对34%),但如果将脑脊液和MRI标准结合,敏感性可进一步提高到60%。同样,tau蛋白和NfHSMI35的组合显示出比MRI更高的特异性(94%对82%)。tau蛋白和NfHSMI35是CIS患者轴突损伤的有价值生物标志物。如果将脑脊液标志物与MRI结合,可改善对CIS转化为MS的预测。

相似文献

1
Axonal damage markers in the cerebrospinal fluid of patients with clinically isolated syndrome improve predicting conversion to definite multiple sclerosis.临床孤立综合征患者脑脊液中的轴突损伤标志物有助于提高预测其转化为确诊多发性硬化症的准确性。
Mult Scler. 2006 Apr;12(2):143-8. doi: 10.1191/135248506ms1263oa.
2
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis.脑脊液中N-乙酰天门冬氨酸与神经丝蛋白在多发性硬化症中的联合研究
Neurology. 2009 Apr 14;72(15):1322-9. doi: 10.1212/WNL.0b013e3181a0fe3f.
3
Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis.在多发性硬化症中,tau蛋白似乎并非轴突损伤的有用常规临床标志物。
Mult Scler. 2006 Jun;12(3):354-6. doi: 10.1191/1352458506ms1288sr.
4
Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.多发性硬化症(MS)队列中的神经胶质和神经轴突生物标志物
Hell J Nucl Med. 2019 Sep-Dec;22 Suppl 2:113-121.
5
Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.脑脊液中的神经胶质和神经元标志物可预测多发性硬化症的病情进展。
Mult Scler. 2015 Apr;21(5):550-61. doi: 10.1177/1352458514549397. Epub 2015 Mar 2.
6
Clinical, magnetic resonance imaging, cerebrospinal fluid and electrophysiological characteristics of the earliest multiple sclerosis.早期多发性硬化症的临床、磁共振成像、脑脊液及电生理特征
Clin Neurol Neurosurg. 2008 Mar;110(3):233-8. doi: 10.1016/j.clineuro.2007.11.001. Epub 2008 Feb 21.
7
Biomarkers of tau phosphorylation state are associated with the clinical course of multiple sclerosis.tau 磷酸化状态的生物标志物与多发性硬化症的临床病程相关。
Mult Scler Relat Disord. 2024 Oct;90:105801. doi: 10.1016/j.msard.2024.105801. Epub 2024 Aug 5.
8
Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis.脑脊液中的tau蛋白:早期复发缓解型多发性硬化症患者预后不良的可能标志物。
Neurosci Lett. 2004 Jun 3;363(1):14-7. doi: 10.1016/j.neulet.2004.03.039.
9
Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsing-remitting multiple sclerosis.临床孤立综合征患者脑脊液中微小RNA-181c的失调与早期转化为复发缓解型多发性硬化症有关。
Mult Scler. 2016 Aug;22(9):1202-14. doi: 10.1177/1352458515613641. Epub 2015 Oct 22.
10
Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.复发型多发性硬化症患者血浆 8,12-iso-iPF2alpha-VI 水平升高与疾病进展无关。
Mult Scler. 2012 Aug;18(8):1092-8. doi: 10.1177/1352458511433306. Epub 2012 Jun 13.

引用本文的文献

1
Can Selected Parameters of Brain Injury Reflect Neuronal Damage in Smoldering Multiple Sclerosis?脑损伤的选定参数能否反映隐匿性多发性硬化中的神经元损伤?
Diagnostics (Basel). 2024 Sep 9;14(17):1993. doi: 10.3390/diagnostics14171993.
2
Pilot Study of the Total and Phosphorylated Tau Proteins in Early-Stage Multiple Sclerosis.早期多发性硬化症中总tau 蛋白和磷酸化 tau 蛋白的初步研究。
Medicina (Kaunas). 2024 Feb 29;60(3):416. doi: 10.3390/medicina60030416.
3
Current use of fluid biomarkers as outcome measures in Multiple Sclerosis (MS): a review of ongoing pharmacological clinical trials.
目前在多发性硬化症(MS)中使用的流体生物标志物作为结局指标:正在进行的药理学临床试验综述。
Neurol Sci. 2024 May;45(5):1931-1944. doi: 10.1007/s10072-023-07228-3. Epub 2023 Dec 20.
4
Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis.用于预测多发性硬化症患者临床疾病进展、恶化和活动的预后模型。
Cochrane Database Syst Rev. 2023 Sep 8;9(9):CD013606. doi: 10.1002/14651858.CD013606.pub2.
5
The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy.多发性硬化早期治疗的全新世界:利用分子生物标志物CXCL13和神经丝轻链优化免疫治疗
Biomedicines. 2022 Aug 28;10(9):2099. doi: 10.3390/biomedicines10092099.
6
The 2022 Lady Estelle Wolfson lectureship on neurofilaments.2022 年埃斯特尔·沃尔夫森夫人神经丝讲座。
J Neurochem. 2022 Nov;163(3):179-219. doi: 10.1111/jnc.15682. Epub 2022 Sep 19.
7
From the prodromal stage of multiple sclerosis to disease prevention.从多发性硬化症的前驱期到疾病预防。
Nat Rev Neurol. 2022 Sep;18(9):559-572. doi: 10.1038/s41582-022-00686-x. Epub 2022 Jul 15.
8
Current and Future Biomarkers in Multiple Sclerosis.多发性硬化症的当前和未来生物标志物。
Int J Mol Sci. 2022 May 24;23(11):5877. doi: 10.3390/ijms23115877.
9
The Role of Tau beyond Alzheimer's Disease: A Narrative Review.Tau蛋白在阿尔茨海默病之外的作用:一篇综述
Biomedicines. 2022 Mar 24;10(4):760. doi: 10.3390/biomedicines10040760.
10
Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.血液和脑脊液中多发性硬化症的新兴生物标志物:聚焦神经丝蛋白及治疗考量
Int J Mol Sci. 2022 Mar 21;23(6):3383. doi: 10.3390/ijms23063383.